Wall Street brokerages predict that Insulet Co. (NASDAQ:PODD) will announce ($0.19) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Insulet’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.26). Insulet reported earnings of ($0.17) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 11.8%. The firm is expected to announce its next quarterly earnings report after the market closes on Thursday, May 3rd.
According to Zacks, analysts expect that Insulet will report full year earnings of ($0.29) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.14). For the next year, analysts anticipate that the firm will post earnings of $0.32 per share, with EPS estimates ranging from $0.04 to $0.71. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Insulet.
Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.04). Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The firm had revenue of $130.50 million during the quarter, compared to analysts’ expectations of $125.16 million. During the same period last year, the business posted ($0.16) EPS. The company’s revenue was up 26.0% compared to the same quarter last year.
In other news, COO Shacey Petrovic sold 1,319 shares of the business’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total transaction of $101,312.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David A. Lemoine sold 641 shares of the business’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total value of $49,235.21. The disclosure for this sale can be found here. Insiders have sold 28,800 shares of company stock valued at $2,412,739 in the last three months. 2.60% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Cerebellum GP LLC purchased a new position in shares of Insulet during the fourth quarter worth about $122,000. Equitec Specialists LLC purchased a new position in shares of Insulet during the fourth quarter worth about $145,000. James Hambro & Partners purchased a new position in shares of Insulet during the fourth quarter worth about $165,000. C M Bidwell & Associates Ltd. purchased a new position in shares of Insulet during the fourth quarter worth about $188,000. Finally, Diversified Trust Co purchased a new position in shares of Insulet during the fourth quarter worth about $218,000.
PODD traded up $2.27 during trading hours on Wednesday, hitting $86.04. The stock had a trading volume of 238,571 shares, compared to its average volume of 516,218. Insulet has a 1 year low of $38.43 and a 1 year high of $88.88. The firm has a market cap of $4,891.42, a P/E ratio of -182.11 and a beta of 1.37. The company has a debt-to-equity ratio of 3.57, a quick ratio of 5.85 and a current ratio of 6.24.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3343846/0-19-eps-expected-for-insulet-co-podd-this-quarter.html.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.